- Report
- August 2025
- 181 Pages
Global
From €3496EUR$3,939USD£3,009GBP
- Report
- August 2025
- 189 Pages
Global
From €3147EUR$3,545USD£2,708GBP
€3496EUR$3,939USD£3,009GBP
- Report
- August 2025
- 185 Pages
Global
From €3147EUR$3,545USD£2,708GBP
€3496EUR$3,939USD£3,009GBP
- Report
- April 2025
- 200 Pages
Global
From €2210EUR$2,490USD£1,902GBP
- Report
- April 2025
- 250 Pages
Global
From €3985EUR$4,490USD£3,430GBP
- Report
- March 2025
- 317 Pages
Global
From €3985EUR$4,490USD£3,430GBP
- Report
- March 2025
- 175 Pages
Global
From €3985EUR$4,490USD£3,430GBP
- Report
- July 2025
- 175 Pages
Global
From €3985EUR$4,490USD£3,430GBP
- Report
- February 2025
- 200 Pages
Global
From €3985EUR$4,490USD£3,430GBP
- Report
- February 2025
- 200 Pages
Global
From €3985EUR$4,490USD£3,430GBP
- Report
- August 2025
- 278 Pages
Global
From €5193EUR$5,850USD£4,469GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1331EUR$1,500USD£1,146GBP
- Report
- June 2025
- 185 Pages
Global
From €3994EUR$4,500USD£3,438GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2476EUR$2,789USD£2,131GBP
- Report
- August 2024
- 137 Pages
Global
From €7057EUR$7,950USD£6,073GBP
- Report
- May 2024
- 137 Pages
Global
From €5769EUR$6,499USD£4,965GBP
- Report
- May 2024
- 138 Pages
Global
From €5769EUR$6,499USD£4,965GBP
- Report
- May 2024
- 131 Pages
Global
From €5769EUR$6,499USD£4,965GBP
- Report
- February 2024
- 182 Pages
Global
From €3994EUR$4,500USD£3,438GBP
- Report
- January 2022
- 60 Pages
Global
From €1331EUR$1,500USD£1,146GBP

Teriparatide is a synthetic form of parathyroid hormone used to treat endocrine and metabolic disorders. It is used to treat osteoporosis in postmenopausal women and men at high risk of fracture, as well as to treat osteoporosis in men and women with glucocorticoid-induced osteoporosis. It is also used to treat Paget's disease of bone in adults. Teriparatide is administered as a subcutaneous injection and is available in both brand-name and generic forms.
Teriparatide is a relatively new drug in the endocrine and metabolic disorders market, but it has been gaining traction in recent years. It is a safe and effective treatment for osteoporosis and other bone-related disorders, and its use is expected to continue to grow.
Some companies in the Teriparatide market include Eli Lilly, Amgen, and Teva Pharmaceuticals. Show Less Read more